Coherus Makes U-Turn On Eylea Biosimilar With Klinge BioPharma Deal

Cash-And-Stock Deal Brings In Exclusive Comm. Rights From Formycon Partner

Buoyed by the recent launch and leverage of its biosimilar ranibizumab biosimilar, Coherus BioSciences has brokered a deal with Klinge BioPharma/Formycon for the commercialization rights to the firms’ Eylea (aflibercept) biosimilar candidate

A U turn arrow traffic symbol imprint on a lonely asphalt road against a blue cloudy sky. - Image
• Source: Shutterstock

Two years ago, Coherus BioSciences shelved development of its wholly-owned CHS-2020 biosimilar Eylea (aflibercept) candidate, several times expressing confidence that with its Cimerli (ranibizumab-eqrn) biosimilar, the company had the “ability to not only penetrate a high degree of Lucentis (ranibizumab) [patients], but also those edges of [off-label] Avastin (bevacizumab) and Eylea (aflibercept).”

But in a twist announced on the first day of the annual J.P. Morgan Healthcare conference, the California-based biotech has...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.